skip to Main Content

LED Medical Announces Change to Distribution Agreement with DenMat Holdings, LLC

  • November 05, 2013
  • News Releases

BURNABY, BRITISH COLUMBIA – November 5, 2013 – LED Medical Diagnostics Inc. (“LED” or the “Company”) announced that as of November 1, 2013,  the global distribution agreement for the VELscope® Vx product line between DenMat Holdings, LLC (“Den-Mat”) and LED Medical Diagnostic’s wholly-owned subsidiary, LED Dental Inc., is no longer an exclusive agreement for North America.

“We’ve arrived at a mutual decision with DenMat that opens the North American market for our VELscope® Vx product line to include more than one distribution partner,” stated Dr. David Gane, LED Medical’s President and CEO. “As a result of this amendment, DenMat will act as a non-exclusive distribution partner in the United States, but will remain exclusive outside of North America.”

About DenMat Holdings, LLC

Since 1974, DenMat has been a leader in high-quality dental products for dental professionals around the world. Headquartered in California, DenMat has over 400 employees and offers three main product categories: consumables, small equipment, and a “one-stop-shop” dental laboratory.  Since September 27, 2012, DenMat had acted as the exclusive global distributor for the VELscope® Vx product line.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol “LMD”, the OTCQX under the symbol “LEDIF”, as well as the Frankfurt Stock Exchange under the symbol “LME”. For more information, visit

Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, the VELscope has sold over 12,000 units, and has been used to perform an estimated 25 million exams. For more information, visit